RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sihuan Pharmaceutical Holdings Group Stock

Sihuan Pharmaceutical Holdings Group Equity 2024

Sihuan Pharmaceutical Holdings Group Equity

4.43 B CNY

Ticker

460.HK

ISIN

BMG8162K1137

WKN

A1C72G

In 2024, Sihuan Pharmaceutical Holdings Group's equity was 4.43 B CNY, a -6.44% increase from the 4.74 B CNY equity in the previous year.

Sihuan Pharmaceutical Holdings Group Aktienanalyse

What does Sihuan Pharmaceutical Holdings Group do?

Sihuan Pharmaceutical Holdings Group Ltd is a leading company in the Chinese pharmaceutical industry that focuses on research, development, production, and marketing of drugs, especially for the treatment of cardiovascular diseases and central nervous system diseases. The company was founded in 2001 and has become one of the largest and most successful companies in the Chinese pharmaceutical industry. It is listed on the stock exchange and has its headquarters in Beijing, China. Sihuan Pharmaceutical's business model is based on a combined strategy of researching and developing new drugs tailored to the Chinese market, as well as licensing and distributing existing drugs from both domestic and international sources. The company is divided into various business divisions to maximize its core competencies and maintain growth. The cardiovascular division is one of the most important divisions, producing and distributing cardiovascular drugs used to treat conditions such as hypertension, heart failure, arrhythmias, and other cardiovascular diseases. The central nervous system division is another important division, producing and distributing drugs to treat neurological disorders such as depression, schizophrenia, and epilepsy. In addition, the company also has products in the areas of antibiotics, antivirals, and gastroenterology. Sihuan Pharmaceutical's research and development department focuses on the discovery and development of new active substances, as well as improving existing drugs. The company collaborates with leading universities and research institutions in China and globally to develop innovative approaches in pharmacy. Sihuan Pharmaceutical has also established a strong presence in the Chinese market, building an extensive distribution network throughout China and working closely with other key players in the industry to strengthen its market position. In summary, Sihuan Pharmaceutical Holdings Group Ltd is a significant player in the Chinese pharmaceutical industry, specializing in the research, development, production, and marketing of drugs for the treatment of cardiovascular diseases and central nervous system diseases. The company is divided into multiple business divisions and has a strong presence in the Chinese market. With its strong research and development department, Sihuan Pharmaceutical is committed to improving the health and well-being of millions of people worldwide. Sihuan Pharmaceutical Holdings Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Sihuan Pharmaceutical Holdings Group's Equity

Sihuan Pharmaceutical Holdings Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Sihuan Pharmaceutical Holdings Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Sihuan Pharmaceutical Holdings Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Sihuan Pharmaceutical Holdings Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Sihuan Pharmaceutical Holdings Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Sihuan Pharmaceutical Holdings Group stock

What is the equity of Sihuan Pharmaceutical Holdings Group this year?

Sihuan Pharmaceutical Holdings Group has equity of 4.43 B CNY this year.

What was the equity of Sihuan Pharmaceutical Holdings Group compared to the previous year?

The equity of Sihuan Pharmaceutical Holdings Group has increased/decreased by -6.44% decreased compared to the previous year.

What impact does a high equity have on investors of Sihuan Pharmaceutical Holdings Group?

A high equity is advantageous for investors of Sihuan Pharmaceutical Holdings Group as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Sihuan Pharmaceutical Holdings Group?

A low equity can be a risk for investors of Sihuan Pharmaceutical Holdings Group, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Sihuan Pharmaceutical Holdings Group affect the company?

An increase in equity of Sihuan Pharmaceutical Holdings Group can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Sihuan Pharmaceutical Holdings Group affect the company?

A reduction in equity of Sihuan Pharmaceutical Holdings Group can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Sihuan Pharmaceutical Holdings Group?

Some factors that can affect the equity of Sihuan Pharmaceutical Holdings Group include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Sihuan Pharmaceutical Holdings Group so important for investors?

The equity of Sihuan Pharmaceutical Holdings Group is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Sihuan Pharmaceutical Holdings Group take to change the equity?

To change equity, Sihuan Pharmaceutical Holdings Group can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Sihuan Pharmaceutical Holdings Group pay?

Over the past 12 months, Sihuan Pharmaceutical Holdings Group paid a dividend of 0.07 CNY . This corresponds to a dividend yield of about 11.4 %. For the coming 12 months, Sihuan Pharmaceutical Holdings Group is expected to pay a dividend of 0.05 CNY.

What is the dividend yield of Sihuan Pharmaceutical Holdings Group?

The current dividend yield of Sihuan Pharmaceutical Holdings Group is 11.4 %.

When does Sihuan Pharmaceutical Holdings Group pay dividends?

Sihuan Pharmaceutical Holdings Group pays a quarterly dividend. This is distributed in the months of October, July, October, November.

How secure is the dividend of Sihuan Pharmaceutical Holdings Group?

Sihuan Pharmaceutical Holdings Group paid dividends every year for the past 16 years.

What is the dividend of Sihuan Pharmaceutical Holdings Group?

For the upcoming 12 months, dividends amounting to 0.05 CNY are expected. This corresponds to a dividend yield of 8.19 %.

In which sector is Sihuan Pharmaceutical Holdings Group located?

Sihuan Pharmaceutical Holdings Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sihuan Pharmaceutical Holdings Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sihuan Pharmaceutical Holdings Group from 10/10/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Sihuan Pharmaceutical Holdings Group pay the last dividend?

The last dividend was paid out on 10/10/2024.

What was the dividend of Sihuan Pharmaceutical Holdings Group in the year 2023?

In the year 2023, Sihuan Pharmaceutical Holdings Group distributed 0.052 CNY as dividends.

In which currency does Sihuan Pharmaceutical Holdings Group pay out the dividend?

The dividends of Sihuan Pharmaceutical Holdings Group are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sihuan Pharmaceutical Holdings Group

Our stock analysis for Sihuan Pharmaceutical Holdings Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sihuan Pharmaceutical Holdings Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.